Article Information
- Received March 11, 2005
- Revision received May 16, 2005
- Accepted May 31, 2005
- First published July 13, 2005.
- Version of record published July 13, 2005.
Author Information
- Dong-Kug Choi1,5,
- Subramaniam Pennathur4,
- Celine Perier1,
- Kim Tieu1,
- Peter Teismann1,
- Du-Chu Wu1,
- Vernice Jackson-Lewis1,
- Miquel Vila1,
- Jean-Paul Vonsattel2,
- Jay W. Heinecke4, and
- Serge Przedborski1,2,3
- 1Neuroscience Research Laboratories of the Movement Disorder Division, Department of Neurology, 2Department of Pathology, and 3Center for Neurobiology and Behavior, Columbia University, New York, New York 10032, 4Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, Washington 98195, and 5Department of Biotechnology, Konkuk University, Chungju-City, Chungbuk 380-701, Korea
Author contributions
Disclosures
- Received March 11, 2005.
- Revision received May 16, 2005.
- Accepted May 31, 2005.
This work was supported by grants from the National Institutes of Health-National Institute of Neurological Disorders and Stroke (NS38586, NS42269, NS38370, NS11766-27A2) and National Institute of Aging (AG021191), the United States Department of Defense Grant (DAMD17-99-1-9474 and DAMD17-03-1), the Lowenstein Foundation, the Lillian Goldman Charitable Trust, the National Institute of Environmental Health Sciences (P30ES07033), the Donald W. Reynolds Foundation, and the Parkinson's Disease Foundation. We thank Matthew Lucas for assistance in preparing this manuscript, Dr. Ernst Malle (University of Graz, Graz, Austria) for providing the HOP-1 antibody, and the New York Brain Bank at Columbia University Taub Institute for providing human Parkinson's disease samples.
Correspondence should be addressed to Dr. Serge Przedborski, Columbia University, 650 West 168th Street, BB-318, New York, NY 10032. E-mail: sp30{at}columbia.edu.
Copyright © 2005 Society for Neuroscience 0270-6474/05/256594-07$15.00/0
